NeuroRx Inc, a clinical stage, small molecule pharmaceutical company, and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF), a Swiss-based publicly-traded drug development company, have received US Food and Drug Administration (FDA) Investigational New Drug (IND) approval to test RLF-100 (aviptadil) for inhaled use in the treatment of patients with moderate and severe COVID-19 in order to prevent progression to respiratory failure, it is reported on Thursday.
The first phase is to start with patients hospitalised for severe COVID-19 who do not yet have respiratory failure. If promising results are revealed then the trial will expand to patients at home with mild and moderate COVID-19 in order to prevent the requirement for hospital admission.
The clinical trial of the product's inhaled formulation is likely to commence on or before 1 September 2020.
Clene Inc closes registered direct offering of common stock to existing shareholders
Insmed's ARIKAYCE sNDA granted priority review by FDA
Precigen announces FDA platform technology designation for AdenoVerse
Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Medtronic receives FDA clearance for LigaSure RAS Maryland instrument on Hugo system
VaxThera partners with Codagenix for next generation yellow fever vaccine advancement
MaaT Pharma receives negative CHMP trend vote for MaaT013
FDA approves Scholar Rock's ISEMBYLD to treat spinal muscular atrophy
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis